Dr. Maegawa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
33 Whiting Hill Road
Eastern Maine Medical Center
Brewer, ME 04412Phone+1 207-973-7478Fax+1 207-973-7807
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 2008 - 2011
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2005 - 2008
Federal University of Parana Faculty of MedicineClass of 2005
Certifications & Licensure
ME State Medical License 2012 - 2026
CA State Medical License 2011 - 2025
NJ State Medical License 2020 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 3 citationsMolecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.Jerald P Radich, Matthew Wall, Susan Branford, Catarina D Campbell, Shalini Chaturvedi
Haematologica. 2023-06-01 - Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review.Ehab Atallah, Lovneet Saini, Rodrigo Maegawa, Tanvi Rajput, Regina Corbin
Therapeutic Advances in Hematology. 2023-01-01 - 4 citationsTyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline upd...Ehab Atallah, Islam Sadek, Rodrigo Maegawa, Xiting Cao, Dominick Latremouille-Viau
Leukemia & Lymphoma. 2021-03-01
Lectures
- Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Maine Patients and Researchers Fighting Cancer – Part 1February 2nd, 2017- Maine Patients and Researchers Fighting Cancer – Part 2February 2nd, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
